Richard L. Kravitz, MD, MSPH and Jodi Halpern, MD, PhD
Patients have a responsibility to discerningly present the drug information they receive from direct-to-consumer advertising and to be active partners with their physician in making health care decisions.
Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
Dr Keith W. Hamilton joins Ethics Talk to discuss his article, coauthored with Dr George Maliha, Keith Robert Thomas, and Mary Ellen Nepps: “How Might Antibiotic Stewardship Programs Influence Clinicians’ Autonomy and Organizations’ Liability?”
A bioethicist argues that children with Down syndrome should not be subjected to cosmetic surgery to change their appearance unless they are at the age and have the capacity to make the decision for themselves.